JuicyBet Launches Its Innovative GambleFi Platform

New York, NY, May 2, 2024 – (ACN Newswire) – JuicyBet, a Web3 startup, announced the launch of its GambleFi platform. This platform combines finance technology and gambling via blockchain to create unique opportunities and experiences for users. The company strives to revolutionize the principles of the online betting industry and the interaction between platforms and users in this market.

What is GambleFi?

GambleFi uses blockchain technology to ensure the fairness and transparency of games and betting outcomes and for players to get their share of the platform’s earnings and participate in its governance and day-to-day by holding its tokens.

How JuicyBet works

JuicyBet fully utilizes blockchain technology to establish a new ecosystem that has never been seen in the gambling industry. It is centered around user participation and transparency while providing gambling thrills and quality entertainment.

All game records on the platform are kept in a public blockchain, while a set of smart contracts automates gaming outcomes and payouts and provides for the platform governance via the DAO model. This reduces fraud risks and operational costs, making JuicyBet a more efficient platform.

However, the platform’s main feature is the unprecedented level of user engagement via the platform’s native tokens.

First, the tokens provide access to betting.
Second, token holders get their share of the platform’s profit.
Third, token holders can vote on key decisions on the platform’s development in JuicyBet DAO.
And finally, DAO participants can also perform the role of oracles for bets and earn rewards.

In other words, JuicyBet doesn’t try to be just another gambling platform. It establishes a new ecosystem where users are in control of the platform and bets and are the beneficiaries of the platform.

In addition, JuicyBet offers additional earning opportunities, such as Double Farming and staking for token holders.

JuicyBet has already been noticed by users and investors – the platform’s 3-month turnover has exceeded $1,5 million, according to on-chain data available via Dune, and multiple centralized exchanges and launchpads have listed it.

In conclusion, it is worth mentioning that GambleFi represents a technologically advanced and transparent opportunity to earn additional income and profits from the usual entertainment while using the flagship GambleFi platform – https://juicybet.net/.

Social Links
X: https://twitter.com/YourJuicyBets
Discord: https://discord.com/invite/JuicyBet
Telegram: https://t.me/YourJuicyBets
Medium: https://medium.com/@juicybet
Zealy: https://zealy.io/cw/juicybet/questboard

Media contact
Brand: JuicyBet
Contact: Media team
Website: https://juicybet.net/

SOURCE: JuicyBet

Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio’s New Botulinum Toxin Development Project

SEOUL, S.KOREA, Apr 26, 2024 – (ACN Newswire) – Dr. Eric A. Johnson and Professor Dirk Dressler, internationally renowned botulinum toxin experts, visited South Korea in March this year to join WizMedi Bio’s new botulinum toxin development project. Their involvement is expected to profoundly boost product development and registration processes.

The long-standing collaboration between Dr. Johnson and Professor Dressler has shaped the global botulinum toxin landscape over the past decades. Dr. Johnson, a retired professor of bacteriology at the University of Wisconsin-Madison in the US, has dedicated over four decades to botulinum toxin research, authoring over 200 publications and founded 3 botulinum toxin companies. His prominent contributions led to the development of the first botulinum toxin drug.

Professor Dressler, the head of the Movement Disorders Section at Hannover Medical School in Germany, has been at the forefront of both translational botulinum toxin research and the development of all significant clinical applications, including dystonia, spasticity, migraine, hyperhidrosis, and aesthetic indications. Having introduced most of the major botulinum toxin drugs to the international markets, he is a highly sought-after consultant to the botulinum toxin industry.

WizMedi Bio recently announced the acquisition of the exclusive rights to the newly developed and patented botulinum toxin type A6 strain from the Wisconsin Alumni Research Foundation(WARF), a subsidiary of the University of Wisconsin.

During their visit to Korea, Dr. Johnson and Professor Dressler visited BNC Korea’s cutting-edge manufacturing and research facilities, solidifying the positive outlook for the project’s success. BNC Korea and WizMedi Bio formed a strategic partnership in 2023 to research and develop new botulinum toxin products.

Dr. Johnson expressed his enthusiasm by saying: ” I am excited about the novelty of A6 botulinum toxin and its potential as a new drug in the growing botulinum field. My visit to WizMedi Bio and their professionalism has only strengthened my confidence in this project.”

Dr. Yonghun Choi, the CEO of WizMedi Bio, said: “The two experts are already mythical figures in the botulinum toxin arena, and it is an absolute delight for us to work with both of them simultaneously. We look forward to working with them to bring our new potent A6 toxin to the market as soon as possible.”

Social Links
Twitter: https://twitter.com/WIZMEDIKR

Media Contact
Company: Wizmedi Co., Ltd.
Contact: Media Team
Website: https://wizmedi.kr

SOURCE: Wizmedi Co., Ltd.

Citi, UBS, GS view positive on Fosun’s core business-focused strategy

HONG KONG, Apr 23, 2024 – (ACN Newswire) – Fosun International (HKEX: 0656) has recently received bullish recommendations from multiple investment banks after announcing its 2023 annual results. On 12 April 2024, Goldman Sachs (GS) issued a research report stating that Fosun’s industrial operation profit reached RMB4.9 billion, up by approximately 20% year-on-year compared to 2022; profit attributable to shareholders of the parent company reached RMB1.38 billion. Goldman Sachs gave Fosun International a target price of HK$4.90, representing an upside of over 13%. Fosun International’s businesses in Health, Happiness and Wealth segments are expected to keep on growing steadily in the future. Goldman Sachs pointed out that although Fosun Pharma was affected by the decline in Covid-related business revenue last year, it expected a sales growth recovery in 2024; Fosun Tourism Group’s attributable profit in 2024 is expected to further improve to RMB321 million on better performance from resort operation and tourism services business; it further pointed out that the insurance business posted a net profit of RMB790 million and the profit from BCP is expected to remain strong in 2024 on elevated interest rate spread.

In its research report published at the end of March, UBS was also optimistic about Fosun International’s strategy of focusing on its core businesses, pointing out that in the future Fosun will continue to execute its disposal plans of exiting non-core assets and concentrate resources on sustainable, predictable and stable core businesses, striving to achieve more efficient resource allocation and profit growth in those areas. UBS believed that with the execution of these disposal plans, Fosun International’s profitability is expected to further improve, based on which it gave a target price of HK$6.30. With the momentum in China’s economy pick up, the execution of streamlining operations and the increasing dividends to shareholders in the future, the valuation of Fosun International will further improve.

Citi Research also issued a report in which it expressed its optimistic views about Fosun International’s market outlook. Citi Research believed that Fosun International’s profitability in 2023 was attributable to an increase in operating profit from the insurance business, a 19.2% year-on-year growth in Club Med’s business volume that exceeded expectations, and better performance in the Asset Management Division which was driven by improvement in the Group’s asset portfolio profitability. The report pointed out that Fosun will continue to look for appropriate opportunities to sell non-core and non-strategic assets and promote future development through synergies amongst subsidiaries. Citi Research gave Fosun a “Buy” rating, with a target price of HK$ 6.30, an expected increase of approximately 57%.

Microex Launches Web3.0 Financial Trading Solution – Pioneering Innovation in Financial Technology

NEW YORK, Apr 17, 2024 – (ACN Newswire) – Microex, a UAE-based financial technology company, today announced the launch of its web3.0 financial trading solution. This innovative platform marks a significant step forward in the financial technology industry.

Since its founding in August 2022, Microex has been dedicated to redefining and revolutionizing derivative trading. The company leverages the potential of Web3 technology to create a more accessible and efficient trading experience. Microex’s emphasis on mini-contracts, AI-driven smart trading bots, and advanced security features has positioned it as a major player in the global financial market.

Microex’s Distinctive Approach

Microex’s innovative mini-trading strategy differentiates it from traditional trading platforms. The core of its offering is the concept of mini-contracts, which allows users to act as mini-liquidity providers for exchanges. This novel approach disrupts existing markets and provides unmatched flexibility for both users and traders. Microex’s win-win strategy fosters a collaborative environment that benefits users, the platform, and market development agents.

Artificial Intelligence and High-Speed Hedging Algorithms

A standout feature of Microex is its AI-powered trading, which has consistently generated stable income for users over the past 19 months. Microex’s proprietary AI algorithms analyze market trends and execute hedging trades simultaneously across various platforms with precision and high speed. This offers users a secure and efficient trading experience in today’s fast-paced environment.

Unwavering Commitment to Security and Transparency

In an age where security is paramount, Microex prioritizes the safety of user funds. Its encrypted wallet features built-in anti-theft protection to safeguard against hacking attempts. Additionally, all transfers on Microex are completed on the blockchain, with the hash value of each transaction permanently stored in a public ledger. This immutable record guarantees the security, transparency, and trustworthiness of every transaction.

Future Development and Expansion:

Since its inception, Microex has transformed from a theoretical concept into a fully functional trading platform with profit-generating strategies. The company has recently obtained financial regulatory licenses in various regions to facilitate global market expansion. In January 2024, Microex was invited to Singapore for a venture capital roadshow by three prominent firms from the United States, Singapore, and Indonesia.

Microex’s achievements within a short timeframe can be attributed to the continuous dedication and innovation of its founder, Mr. Peng, and his team. Their unwavering commitment to excellence extends across all aspects of the business, from technical development and company management to market development.

Looking Ahead: Shaping the Future of Finance

In 2024, Microex will focus on developing decentralized applications (DApps) to streamline trading and portfolio management. The company is also developing a groundbreaking tool for recovering stolen cryptocurrencies. Additionally, Microex is exploring the integration of Web3 elements and non-fungible authority (NFA) tokens. These dynamic elements have the potential to revolutionize the financial landscape through smart contracts and community-driven decisions.

By 2025, Microex plans to develop and enhance more ecosystems, leveraging its vast trading data and user base to create even greater value. This positions Microex to shape the future of finance, redefine trading and investment methods, and usher in a new era of one-minute trading in the global financial market.

Social Links
X: https://twitter.com/MVG_MicroEx
Discord: https://medium.com/@microex.social
Instagram: https://www.instagram.com/mvg_microex/
Facebook: https://www.facebook.com/microventuregroup

Media contact
Brand: Microex
Contact: Media team
Website: https://www.microex.io/

SOURCE: Microex

To acquire stake in Hangzhou Bizike, Phoenitron Holdings has eye on trillion-dollar e-commerce market

HONG KONG, Apr 17, 2024 – (ACN Newswire) – Beijing Tecsun Venus Technology Limited, an indirect wholly-owned subsidiary of Phoenitron Holdings Limited (8066.HK), has entered into a capital injection agreement with Hangzhou Bizike Intelligence Technology Company Limited stating its intention to subscribe registered capital of Hangzhou Bizike. When the transaction is completed, Beijing Tecsun Venus will hold 20% of the enlarged registered capital of Hangzhou Bizike. It will mark the Group’s formal entry into the trillion-dollar e-commerce market in the PRC, as well as enable it to expand its business and broaden its income sources.

The e-commerce market in the PRC has continued to grow over the past few years. That and the outbreak of the COVID-19 pandemic have driven consumers to shop online and in turn speeded up growth of the country’s e-commerce market, short video platforms and live stream commerce, encouraging businesses to pursue offline-to-online transformation, with success hinging on online marketing and sales through online KOL livestreaming. According to the market research company eMarketer, the retail e-commerce market of the PRC is expected to continue its growth and reach approximately RMB28.8 trillion in 2027, indicative of its huge development potential.

To Phoenitron, the thriving e-commerce market presents it with an important opportunity that agrees with its growth strategy and aim to diversity business. Thus, the decision to acquire Hangzhou Bizike, which is in e-commerce business, to support the Group in attaining strong growth of its business in the future and of its ability to generate revenue. Hangzhou Bizike’s main business is to market and sell merchandises via livestreaming, and it also provides short video marketing and creates IP for KOLs. It started preparations for its livestreaming business at the end of 2022, focusing on three main highest ROI (Return-on-Investment) product categories, namely womenswear, health products and beauty products, and started to record revenue in 2023. In just 10 months between June 2023 and March 2024, the transaction value generated through livestreaming exceeded RMB90 million, which was rather remarkable.

At present, Hangzhou Bizike is serving a famous Chinese women’s clothing brands, while also actively expanding its own brands and already has the brand LULU OCEAN registered. The brand specializes in women’s sportswear for all seasons, such as yoga wear. Hangzhou Bizike plans to use funds from the transaction on livestreaming of its own proprietary brands to promote product sales. What’s noteworthy is the company’s senior management is made up of former senior personnel of e-commerce platforms such as “Alibaba” and the leading short-video platform “douyin”. Bringing with them profound relevant experience, they have seen Hangzhou Bizike claim the top spot among livestreaming platforms on the Tencent Video streaming website.

The capital injection will allow Phoenitron to make Hangzhou Bizike’s livestreaming capability its own, foray into e-commerce business, build its own proprietary brand and capitalize on the growth momentum of the retail e-commerce market of the PRC. It is clear that the Group, via pursuing its active business development plan, is continuously exploring growth opportunities in different fields and such efforts will open more room for growth to it in the future.

The Group has recently announced its 2023 results, with revenue up by a notable 35.3% to approximately HK$79.1 million, and turning around from net loss last year to net profit of approximately HK$4.3 million. Such results plus the capital injection will prompt the market to re-evaluate Phoenitron’s worth, acting as an important catalyst to the Group’s market performance in the short term. In the long run, at its continuous effort to expand business and enhance profitability, the Group will have a solid foundation for future development and its long-term value will continue to show and catch eyes.

To acquire stake in Hangzhou Bizike, Phoenitron Holdings has eye on trillion-dollar e-commerce market

Microex Launches Web3.0 Financial Trading Solution – Pioneering Innovation in Financial Technology

Microex’s Distinctive Approach

Artificial Intelligence and High-Speed Hedging Algorithms

Unwavering Commitment to Security and Transparency

Future Development and Expansion:

Looking Ahead: Shaping the Future of Finance

Social Links
X: https://twitter.com/MVG_MicroEx
Discord: https://medium.com/@microex.social
Instagram: https://www.instagram.com/mvg_microex/
Facebook: https://www.facebook.com/microventuregroup

Media contact
Brand: Microex
Contact: Media team
Website: https://www.microex.io/

SOURCE: Microex

FBS Releases a Major Update to Mobile App: Everything Is Now in Users’ Smartphone

Belize City, Belize, Apr 11, 2024 – (ACN Newswire) – FBS, a leading global broker, introduces its revamped mobile trading application – the FBS app. The upgraded solution is available for Android and iOS users, providing them with all the tools and resources for online trading. To thank clients for choosing FBS, the broker launches exclusive in-app promotions, cutting spreads by half on several instruments throughout April and in early May.

The new FBS app is designed to evolve into an all-in-one trading solution. Everything is available at the user’s fingertips – from registration and account creation to opening and closing orders and funds management. The upgraded FBS app transforms trading experience, allowing users to seize market opportunities on the go, anytime.

To help its clients uncover their trading potential, FBS additionally announces exclusive trading conditions for application users. During the four weeks after the release day, the FBS app will send daily alerts about designated happy trading hours, when spreads will be cut by 50% on select instruments, starting with the Gold – US dollar (XAUUSD) pair.

In addition to the enhanced mobile experience, FBS continues to offer exceptional trading conditions, including:

550+ trading instruments and zero overnight fees for trading Forex majors;
Fast and stable order execution from 0.01 seconds;
Tight spreads from 0.7 pips;
High leverages up to 1:3000;
Availability of VPS hosting for automated trading;
No hidden commissions.

FBS is committed to continuous improvement and ensures that traders have access to cutting-edge technology and exceptional trading conditions. The launch of the FBS app marks a significant milestone for the global broker. FBS will continue working on its mission to help clients maintain an efficient trading lifestyle and achieve their financial goals.

To learn more about FBS and the FBS app, visit www.fbs.com.

About FBS

FBS is a licensed global broker with 15 years of experience and more than 90 international awards. FBS is steadily developing as one of the market’s most trusted brokers, with its traders numbering more than 27,000,000 and its partners exceeding 700,000 around the globe. The annual trading volume of FBS clients is over $8.9 trillion. FBS is also the Official Partner of Leicester City Football Club.

Media Contact
Company: FBS
Contact: The FBS Press Office
Website: https://fbs.com/

SOURCE: FBS

WizMediBio Signs Contract with the Wisconsin Alumni Research Foundation (WARF) for Botulinum Toxin Strain

SEOUL, S.KOREA, Apr 9, 2024 – (ACN Newswire) – WizMedi Bio Co., Ltd. (WizMedi Bio) today announced that it has reached a formal agreement with the Wisconsin Alumni Research Foundation (WARF), established by the University of Wisconsin, for the patent and technical licensing of the A6 botulinum neurotoxin strain. This agreement enables WizMedi Bio to prove the origin of the strain, which has been the primary hurdle to the botulinum toxin business, and paves a pathway to develop a stable new business in the market.

The A1 botulinum toxin currently dominates the market and as a novel subtype, A6 presents itself as a challenger. Therefore, the future course of the A6 strain as a BOTULINUM TOXIN provides a new opportunity in the botulinum field. According to research published by Dr. Eric A. Johnson and colleagues, the A6 strain is known to have high potency and long duration of action in animal models. Evidence indicates the toxin is also known to stay long in local areas. Due to its high potency with fewer side effects, the A6 strain is expected to bring a new perspective to the market.

WizMedi Bio has signed consulting agreements with world-renowned scholars in this field and announced that it will actively target not only the Korean domestic market but also the U.S. market, which is a challenging market to enter. To bring A6 to commerce, the company has also signed an agreement for a strategic alliance with BNC Korea, Inc. (http://bnckorea.co.kr/), utilizing their GMP botulinum toxin facility, for joint research and development. Moreover, the company will actively work in tandem with the FDA to secure a production facility in the U.S.

WizMedi Bio was co-founded by two medical doctors based on their expertise and know-how gained at WizMedi Co., Ltd., a company dedicated to the research and development of products targeted at the beauty and medical aesthetic markets. The company aims to capture the botulinum toxin market based on maximized utilization of its distribution network and experience. In particular, it will actively target the U.S. market, which accounts for more than 60% of the global market.

“We will enhance the global market, especially the U.S., with novel botulinum toxin products,” said Choi Yong-hoon, the CEO of WizMedi Bio.

Social Links
Twitter: https://twitter.com/WIZMEDIKR

Media Contact
Company: Wizmedi Co., Ltd.
Contact: Media Team
Website: https://wizmedi.kr

SOURCE: Wizmedi Co., Ltd.

Exosens Adds Innovative Photon Counting System, LINCam, to Its Portfolio of Single Photon Sensitive Detectors

RODEN, NETHERLANDS, Apr 9, 2024 – (ACN Newswire) – Exosens is pleased to announce a partnership with Photonscore, a provider of instrumentation for time-correlated single photon imaging. Through this partnership, Exosens will distribute LINCam, an innovative camera system with picosecond time resolution through their Photonis-branded scientific imaging product portfolio.

Exosens & Photonscore Partnership

“We are delighted to partner with Photonscore and add LINCam to our scientific imaging solutions to our potential customers. LINCam is a breakthrough technology that enables fast and accurate time-resolved imaging for a variety of applications, such as biomedical research, material science, and quantum optics. LINCam complements our existing product line and combined will provide a unique value proposition.” – Ulrich Laupper, President and Executive General Manager of the Exosens Ultimate Detection Business Unit.

LINCam is an easy-to-use, event-based camera that counts photons at high rate with the picosecond time resolution combined with accurate position information. Paired with a pulsed light source, LINCam can turn any conventional microscope into a powerful lifetime imager.

The partnership between Exosens and Photonscore is supported by Photonis, a brand of Exosens, which provides a crucial component of the camera: the high-time resolution position-sensitive MCP-PMT detector. Photonis has optimized the MCP-PMT which allows for the best properties for LINCam performance by providing high quantum efficiency and low dark rate photocathodes in a broad spectral range and also by implementing high linearity and high gain MCPs to increase the dynamic operational range. As a result of Exosens and Photonscore’s close technical collaboration, the state-of-the-art high-time resolution single-photon camera LINCam becomes the optimal solution for widefield microscopy and other highly demanding applications.

“At Photonscore we are excited to start a productive partnership with Exosens. Their knowledge and experience in the field of photon detection gave us a big leap in the quality and capability of our system. In particular, the outstanding technology of Hi-QE photocathodes and high-performance MCPs enables us to bring LINCam to the applications where we did not dare enter into before.” – Yury Prokazov, CEO, Photonscore GmbH

ABOUT PHOTONSCORE:

Photonscore GmbH specializes in simplifying single photon counting for its customers. The company’s primary product, the LINCam, is a single photon counting camera with a 100% fill-factor and minimal noise. The company is serving leading universities and research institutes across the world, reflecting the broad applicability of its technologies. Photonscore’s contributions to the field have been recognized with several awards. These include the 1st Prize in the Hugo-Junkers-Award 2017 for innovative applied research and nomination as a finalist in the German Innovation Award 2019. Photonscore is committed to advancing photon counting technology, striving to make it more accessible and effective for a wide range of applications.

ABOUT PHOTONIS:

Photonis is a leading brand of Exosens, a high-tech company with more than 85 years of experience in the innovation, development, manufacture, and sale of high-end electro-optical technologies used in the detection of ions, electrons, and photons. The Photonis brand portfolio offers photo-detection and low-light conditions imaging solutions for extremely demanding markets such as Defense & Security, Nuclear Safety, Life Science, and Industrial & Non-Destructive testing. Photonis is internationally recognized as a leading brand and a major innovator in its fields with production and R&D sites in Europe and North America.

For more information: exosens.com

Contact: scientificdetectors@exosens.com

Contact Information
Sales Manager
scientificdetectors@exosens.com
+31 50 501 8808

SOURCE: Photonis

View the original press release on newswire.com.